FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4289861239> ?p ?o ?g. }

• W4289861239 endingPage "1631" @default.
• W4289861239 startingPage "1631" @default.
• W4289861239 abstract "Fungal keratitis, a disease in which the cornea becomes inflamed due to an invasive fungal infection, remains difficult to treat due in part to limited choices of available treatments. Topical eye drops are first-line treatment, but can be ineffective as low levels of drug reach the target site due to precorneal losses and the impenetrability of the cornea. The aim of this study was to determine the corneal delivery of econazole using a novel topical enhancement approach using a composite delivery system based upon cyclodextrins and soft hydrogel contact lenses. Excess econazole nitrate was added to hydroxypropyl-α-cyclodextrin (HP-α-CD) and hydroxypropyl-β-cyclodextrin (HP-β-CD) solutions, and the solubility determined using HPLC. Proprietary soft hydrogel contact lenses were then impregnated with saturated solutions and applied to freshly enucleated porcine eyeballs. Econazole nitrate ‘eye drops’ at the same concentrations served as the control. After 6 h, the corneas were excised and drug-extracted, prior to quantification using HPLC. Molecular dynamic simulations were performed to examine econazole−HP-β-CD inclusion complexation and dissociation. The minimum inhibitory concentration (MIC) of econazole was determined against four fungal species associated with keratitis, and these data were then related to the amount of drug delivered to the cornea, using an average corneal volume of 0.19 mL. The solubility of econazole increased greatly in the presence of HP-β-CD and more so with HP-α-CD (p < 0.001), with ratios >> 2. Hydrogel contact lenses delivered ×2.8 more drug across the corneas in comparison to eye drops alone, and ×5 more drug delivered to the cornea when cyclodextrin was present. Molecular graphics demonstrated dynamic econazole release, which would create transient enhanced drug concentration at the cornea surface. The solution-only drops achieved the least satisfactory result, producing sub-MIC levels with factors of ×0.81 for both Fusarium semitectum and Fusarium solani and ×0.40 for both Scolecobasidium tshawytschae and Bipolaris hawaiiensis. All other treatments delivered econazole at > MIC for all four fungal species. The efficacies of the delivery platforms evaluated were ranked: HP-α-CD contact lens > HP-β-CD contact lens > contact lens = HP-α-CD drops > HP-β-CD drops > solution-only drops. In summary, the results in this study have demonstrated that a composite drug delivery system based upon econazole−HP-β-CD inclusion complexes loaded into contact lenses can achieve significantly greater corneal drug delivery with the potential for improved clinical responses." @default.
• W4289861239 created "2022-08-05" @default.
• W4289861239 creator A5010495560 @default.
• W4289861239 creator A5015673448 @default.
• W4289861239 creator A5017758211 @default.
• W4289861239 creator A5018350439 @default.
• W4289861239 creator A5028624040 @default.
• W4289861239 creator A5036328699 @default.
• W4289861239 creator A5077065421 @default.
• W4289861239 creator A5089221213 @default.
• W4289861239 date "2022-08-04" @default.
• W4289861239 modified "2023-10-16" @default.
• W4289861239 title "A Composite System Based upon Hydroxypropyl Cyclodextrins and Soft Hydrogel Contact Lenses for the Delivery of Therapeutic Doses of Econazole to the Cornea, In Vitro" @default.
• W4289861239 cites W1592505922 @default.
• W4289861239 cites W1794991732 @default.
• W4289861239 cites W1966491272 @default.
• W4289861239 cites W1975231832 @default.
• W4289861239 cites W1978285976 @default.
• W4289861239 cites W1980694455 @default.
• W4289861239 cites W1986208662 @default.
• W4289861239 cites W1994438083 @default.
• W4289861239 cites W2006894346 @default.
• W4289861239 cites W2020213878 @default.
• W4289861239 cites W2023772978 @default.
• W4289861239 cites W2037927370 @default.
• W4289861239 cites W2048384946 @default.
• W4289861239 cites W2054384419 @default.
• W4289861239 cites W2054747660 @default.
• W4289861239 cites W2055091943 @default.
• W4289861239 cites W2059527049 @default.
• W4289861239 cites W2060384870 @default.
• W4289861239 cites W2061549163 @default.
• W4289861239 cites W2064185190 @default.
• W4289861239 cites W2070332894 @default.
• W4289861239 cites W2071128876 @default.
• W4289861239 cites W2075223755 @default.
• W4289861239 cites W2135179505 @default.
• W4289861239 cites W2142553680 @default.
• W4289861239 cites W2156932023 @default.
• W4289861239 cites W2285775554 @default.
• W4289861239 cites W2290280012 @default.
• W4289861239 cites W2324350546 @default.
• W4289861239 cites W2405222216 @default.
• W4289861239 cites W2411800135 @default.
• W4289861239 cites W2524286434 @default.
• W4289861239 cites W2557136389 @default.
• W4289861239 cites W2566513687 @default.
• W4289861239 cites W2604702513 @default.
• W4289861239 cites W2736411991 @default.
• W4289861239 cites W2738567488 @default.
• W4289861239 cites W2772437675 @default.
• W4289861239 cites W2781877382 @default.
• W4289861239 cites W2786080353 @default.
• W4289861239 cites W3003174538 @default.
• W4289861239 cites W3210224386 @default.
• W4289861239 cites W81339268 @default.
• W4289861239 doi "https://doi.org/10.3390/pharmaceutics14081631" @default.
• W4289861239 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/36015257" @default.
• W4289861239 hasPublicationYear "2022" @default.
• W4289861239 type Work @default.
• W4289861239 citedByCount "4" @default.
• W4289861239 countsByYear W42898612392023 @default.
• W4289861239 crossrefType "journal-article" @default.
• W4289861239 hasAuthorship W4289861239A5010495560 @default.
• W4289861239 hasAuthorship W4289861239A5015673448 @default.
• W4289861239 hasAuthorship W4289861239A5017758211 @default.
• W4289861239 hasAuthorship W4289861239A5018350439 @default.
• W4289861239 hasAuthorship W4289861239A5028624040 @default.
• W4289861239 hasAuthorship W4289861239A5036328699 @default.
• W4289861239 hasAuthorship W4289861239A5077065421 @default.
• W4289861239 hasAuthorship W4289861239A5089221213 @default.
• W4289861239 hasBestOaLocation W42898612391 @default.
• W4289861239 hasConcept C118487528 @default.
• W4289861239 hasConcept C136229726 @default.
• W4289861239 hasConcept C16005928 @default.
• W4289861239 hasConcept C178790620 @default.
• W4289861239 hasConcept C185592680 @default.
• W4289861239 hasConcept C2776778513 @default.
• W4289861239 hasConcept C2776882836 @default.
• W4289861239 hasConcept C2777229883 @default.
• W4289861239 hasConcept C2778560704 @default.
• W4289861239 hasConcept C2779548794 @default.
• W4289861239 hasConcept C2779820397 @default.
• W4289861239 hasConcept C43617362 @default.
• W4289861239 hasConcept C71924100 @default.
• W4289861239 hasConcept C98274493 @default.
• W4289861239 hasConceptScore W4289861239C118487528 @default.
• W4289861239 hasConceptScore W4289861239C136229726 @default.
• W4289861239 hasConceptScore W4289861239C16005928 @default.
• W4289861239 hasConceptScore W4289861239C178790620 @default.
• W4289861239 hasConceptScore W4289861239C185592680 @default.
• W4289861239 hasConceptScore W4289861239C2776778513 @default.
• W4289861239 hasConceptScore W4289861239C2776882836 @default.
• W4289861239 hasConceptScore W4289861239C2777229883 @default.
• W4289861239 hasConceptScore W4289861239C2778560704 @default.
• W4289861239 hasConceptScore W4289861239C2779548794 @default.
• W4289861239 hasConceptScore W4289861239C2779820397 @default.
• W4289861239 hasConceptScore W4289861239C43617362 @default.

• next